Among product type segments, the insulin pen segment in the global insulin delivery systems market is estimated to account for a major revenue contribution of US$ 5,459.1 Mn in 2017. Among the distribution channel segments, the hospital segment is estimated to account for major revenue contribution of US$ 5,274.5 Mn in 2017.
In addition, North America accounted for major revenue contribution in the global insulin delivery systems market, as compared to that of other regions and is estimated to account for a value of US$ 4,276.2 Mn in 2017.
Insulin delivery systems are used to inject measured doses of insulin through the skin. Increasing prevalence of diabetes and technological advancements in insulin delivery systems are major factors expected to drive growth of the global insulin delivery systems market over the forecast period. In addition, increasing government initiative through funding for development of new and risk free insulin delivery systems is another factor expected to fuel growth of the global insulin delivery systems market.
However, high cost associated with development of insulin delivery systems is expected to hamper growth of the global insulin delivery systems market to a certain extent.
Major and growing trend in the market is introduction of wireless insulin pen that can be connected to a smartphone and automatically dispenses the required dosage of insulin is another factor expected to propel growth of the global insulin delivery market over the forecast period.
Key companies in this report are Becton, Dickinson and Company, Eli Lilly and Company, Medtronic plc, Sanofi, Hoffmann-La Roche Ltd., Cellnovo Limited, Insulet Corporation, Tandem Diabetes Care, Inc., Companion Medical, Inc., Copernicus Sp. z o.o.